Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Naturally Splendid Enterprises Ltd V.NSP.H

Alternate Symbol(s):  NSPDF

Naturally Splendid Enterprises Ltd. is a Canada-based company, which develops and distributes healthy lifestyle foods and products. The Company owns Prosnack Natural Foods Inc. (Prosnack Natural Foods), a food manufacturing facility. Prosnack Natural Foods focusses on nutritional bars, Chii Naturally Pure Hemp, which is a retail line of hemp food products, while Pawsitive FX is a line of all natural balms for dogs. The Company has also developed technologies for the extraction of healthy omega three and six oils, as well as a protein concentrate from hemp. It focuses on manufacturing and distributing an extensive line of plant-based, meat-alternative entrees. It offers functional foods under brands, such as Natera Sport, Natera Hemp Foods, CHII and Elevate Me.


TSXV:NSP.H - Post by User

Comment by Qwerty123456on Oct 08, 2020 1:48pm
128 Views
Post# 31689677

RE:NSP news - New Website & Provides Strategic Update

RE:NSP news - New Website & Provides Strategic UpdateGood day, has anyone heard specifics on the status of the Cavaltinib phase 2 trials as referenced in the last NR? Thanks.


"Through the Plasm Pharmaceutical joint venture with Biologic Pharmamedical, the Company continues to pursue a phase 2 clinical trial for a potential COVID-19 treatment utilizing the target drug CavaltinibTM, a curcumin extract derived from a Biologic patented technology."
<< Previous
Bullboard Posts
Next >>